JP2009508960A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009508960A5 JP2009508960A5 JP2008532341A JP2008532341A JP2009508960A5 JP 2009508960 A5 JP2009508960 A5 JP 2009508960A5 JP 2008532341 A JP2008532341 A JP 2008532341A JP 2008532341 A JP2008532341 A JP 2008532341A JP 2009508960 A5 JP2009508960 A5 JP 2009508960A5
- Authority
- JP
- Japan
- Prior art keywords
- pparγ agonist
- kit according
- subject
- pparγ
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 29
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 10
- 108700028369 Alleles Proteins 0.000 claims 9
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 229960004586 rosiglitazone Drugs 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical group N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 claims 1
- 229950003707 farglitazar Drugs 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical group C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 229960004270 nabumetone Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960003271 rosiglitazone maleate Drugs 0.000 claims 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical group C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71935305P | 2005-09-22 | 2005-09-22 | |
| US72737705P | 2005-10-17 | 2005-10-17 | |
| PCT/US2006/036603 WO2007038115A2 (en) | 2005-09-22 | 2006-09-20 | Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009508960A JP2009508960A (ja) | 2009-03-05 |
| JP2009508960A5 true JP2009508960A5 (cg-RX-API-DMAC10.html) | 2009-11-12 |
Family
ID=37876831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532341A Pending JP2009508960A (ja) | 2005-09-22 | 2006-09-20 | ＡＰＯＥ４陰性患者における認識機能の改善のためのＰＰＡＲγアゴニスト |
| JP2008532338A Pending JP2009508959A (ja) | 2005-09-22 | 2006-09-20 | 認識機能の改善のためのロシグリタゾンおよびドネペジルの組合せ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532338A Pending JP2009508959A (ja) | 2005-09-22 | 2006-09-20 | 認識機能の改善のためのロシグリタゾンおよびドネペジルの組合せ |
Country Status (16)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| WO2009043593A1 (en) * | 2007-10-05 | 2009-04-09 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using memantine and glitazones |
| EP2085120A1 (en) * | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| KR20160127181A (ko) | 2008-08-12 | 2016-11-02 | 진판델 파마슈티컬스 인코포레이티드 | 질환 위험 인자의 식별 방법 |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| US20100152249A1 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of The Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| NZ597319A (en) * | 2009-06-25 | 2014-06-27 | Alcobra Ltd | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| WO2012053016A1 (en) * | 2010-10-22 | 2012-04-26 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
| CN107362165A (zh) | 2011-01-10 | 2017-11-21 | 金帆德尔制药股份有限公司 | 用于治疗阿尔茨海默病的方法和药物产品 |
| BR112013017444A2 (pt) * | 2011-01-10 | 2016-09-27 | Zinfandel Pharmaceuticals Inc | método de determinar o risco para o desenvolvimento da doença de alzheimer em um indivíduo, de tratar um indivíduo para a doença de alzheimer e de determinar um risco para desenvolver a doença de alzheimer em um paciente |
| AP2014007645A0 (en) | 2011-10-21 | 2014-05-31 | Takeda Pharmaceutical | Sustained-release preparation |
| CA2853100A1 (en) * | 2011-10-24 | 2013-05-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
| US20160113913A1 (en) * | 2013-04-19 | 2016-04-28 | Takeda Pharmaceutical Company Limited | Controlled-release drug formulation |
| JP6961694B2 (ja) * | 2016-07-26 | 2021-11-05 | オージオ・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | Ｓ−エコールを用いてアルツハイマー病を診断するおよび治療する方法 |
| US20180153859A1 (en) * | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
| KR102224917B1 (ko) | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2142300C (en) * | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| ATE476978T1 (de) * | 1998-12-17 | 2010-08-15 | Mindset Biopharmaceuticals Usa | Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns |
| WO2005074917A1 (en) * | 2004-01-30 | 2005-08-18 | Axonyx, Inc. | Methods for treatment of complications of diabetes |
-
2006
- 2006-09-20 EA EA200800879A patent/EA200800879A1/ru unknown
- 2006-09-20 JP JP2008532341A patent/JP2009508960A/ja active Pending
- 2006-09-20 JP JP2008532338A patent/JP2009508959A/ja active Pending
- 2006-09-20 AU AU2006295007A patent/AU2006295007A1/en not_active Abandoned
- 2006-09-20 TW TW095134699A patent/TW200803896A/zh unknown
- 2006-09-20 KR KR1020087009286A patent/KR20080058413A/ko not_active Withdrawn
- 2006-09-20 BR BRPI0616192-8A patent/BRPI0616192A2/pt not_active Application Discontinuation
- 2006-09-20 EP EP06815011A patent/EP1926488A2/en not_active Withdrawn
- 2006-09-20 EP EP06803887A patent/EP1940403A2/en not_active Withdrawn
- 2006-09-20 TW TW095134700A patent/TW200803851A/zh unknown
- 2006-09-20 CA CA002623210A patent/CA2623210A1/en not_active Abandoned
- 2006-09-20 WO PCT/US2006/036597 patent/WO2007038112A2/en not_active Ceased
- 2006-09-20 US US12/067,374 patent/US20080262047A1/en not_active Abandoned
- 2006-09-20 KR KR1020087009295A patent/KR20080056731A/ko not_active Withdrawn
- 2006-09-20 BR BRPI0616100-6A patent/BRPI0616100A2/pt not_active Application Discontinuation
- 2006-09-20 WO PCT/US2006/036603 patent/WO2007038115A2/en not_active Ceased
- 2006-09-20 US US12/067,382 patent/US20080226719A1/en not_active Abandoned
- 2006-09-20 AU AU2006295010A patent/AU2006295010A1/en not_active Abandoned
- 2006-09-20 EA EA200800880A patent/EA200800880A1/ru unknown
- 2006-09-20 CA CA002623204A patent/CA2623204A1/en not_active Abandoned
- 2006-09-21 PE PE2006001143A patent/PE20070976A1/es not_active Application Discontinuation
- 2006-09-21 PE PE2006001145A patent/PE20070618A1/es not_active Application Discontinuation
- 2006-09-25 AR ARP060104148A patent/AR056527A1/es unknown
- 2006-09-25 AR ARP060104149A patent/AR055649A1/es unknown
-
2008
- 2008-03-17 IL IL190217A patent/IL190217A0/en unknown
- 2008-03-17 IL IL190224A patent/IL190224A0/en unknown
- 2008-03-28 CR CR9848A patent/CR9848A/es not_active Application Discontinuation
- 2008-03-28 CR CR9849A patent/CR9849A/es not_active Application Discontinuation
- 2008-04-15 MA MA30850A patent/MA29872B1/fr unknown
- 2008-04-15 MA MA30849A patent/MA29871B1/fr unknown
- 2008-04-16 NO NO20081843A patent/NO20081843L/no not_active Application Discontinuation
- 2008-04-16 NO NO20081847A patent/NO20081847L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hillman et al. | A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease | |
| US8552041B2 (en) | Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | |
| CN102647982B (zh) | 使用1,3-二苯基丙-2-烯-1-酮衍生物治疗肝脏疾患 | |
| Lefebvre et al. | The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension | |
| US20130095179A1 (en) | Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy | |
| JP2007119479A5 (cg-RX-API-DMAC10.html) | ||
| JP2011219496A (ja) | 高脂血症又はインスリン非依存性糖尿病の予防及び／又は治療のための医薬 | |
| JP2015503583A5 (cg-RX-API-DMAC10.html) | ||
| TW200803896A (en) | Method of improvement of cognitive function | |
| Todo et al. | Usefulness of implementing comprehensive pharmaceutical care for metastatic renal cell carcinoma outpatients treated with pazopanib | |
| Sanghai et al. | Formulation of bilayer benzydamine HCl patch targeted for gingivitis | |
| Schmitz et al. | Dipyrone (metamizole) markedly interferes with platelet inhibition by aspirin in patients with acute and chronic pain: a case-control study | |
| Božina et al. | Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review | |
| JP2009513663A5 (cg-RX-API-DMAC10.html) | ||
| US10765630B2 (en) | Methods and compositions to treat enteropathic arthritis | |
| Robak et al. | The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies | |
| La Corte et al. | Prophylaxis and treatment of NSAID-induced gastroduodenal disorders | |
| Angeletti et al. | Tramadol extended‐release for the management of pain due to osteoarthritis | |
| CN1874754A (zh) | 控释镇痛悬浮液 | |
| JP2006516141A5 (cg-RX-API-DMAC10.html) | ||
| Márkus et al. | Association of PPAR alpha intron 7 G/C, PPAR gamma 2 Pro12Ala, and C161T polymorphisms with serum fetuin‐a concentrations | |
| Lee et al. | CYP2C19 polymorphism in Korean patients on warfarin therapy | |
| EP1605929A1 (en) | Non-steroidal anti-inflammatory drug dosing regimen | |
| Wang et al. | Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers | |
| Hassan et al. | Appropriateness of timing of drug administration in electronic prescriptions |